Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + capecitabine
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
SHR-A1811 + capecitabine is a combination therapy under investigation for the treatment of unresectable or metastatic breast cancer with low HER2 expression. SHR-A1811 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor payload. It targets HER2-expressing tumor cells, delivering the cytotoxic agent directly to these cells to induce cell death. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), classified as an antimetabolite, which interferes with DNA synthesis in rapidly dividing cancer cells. The combination aims to leverage the targeted cytotoxicity of SHR-A1811 and the systemic chemotherapeutic effect of capecitabine for enhanced efficacy in patients whose tumors express low levels of HER2[1][4][6].
- Brand names
- Xeloda
- Other names
- none
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on SHR-A1811 + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + capecitabine.